美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-031 美康生物科技股份有限公司 关于召开 2024 年年度股东大会的提示性公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 美康生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开 了第五届董事会第十二次会议，会议审议通过了《关于召开公司 2024 年年度股 东大会的议案》，公司决定于 2025 年 5 月 23 日（星期五）召开公司 2024 年年度 股东大会，相关内容详见公司于 2025 年 4 月 19 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上刊登的相关公告（公告编号：2025-022）。 本次股东大会将采取网络投票和现场投票相结合的方式召开，为保护投资者 合法权益，方便各位股东行使股东大会表决权，现将有关事项提示公告如下： 一、本次股东大会召开的基本情况 2、会议召集人：公司第五届董事会 3、会议召开的合法、合规性：经公司第五届董事会第十二次会议审议通过， 召集程序符合有关法律、行政法规、部门规章、规范性文 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-030 美康生物科技股份有限公司 上述《注册证》的取得，丰富了公司在体外诊断质谱细分领域产品线的品种， 有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生 积极影响。上述产品实际销售情况取决于未来市场推广效果，公司目前尚无法预 测其对公司未来业绩的影响，敬请投资者注意投资风险。 三、备查文件 1 / 2 关于公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司(以下简称"美康生物"或"公司")于近日取得 了由浙江省药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断 试剂）》（以下简称"《注册证》"），具体情况如下： | 序号 | 注册人名称 | 产品名称 | 注册证编号 | 注册证有效期间 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 美康生物 | 卡马西平质控品 | 浙 械注准 | 2025 年 5 月 7 日至 | 与本公司生产的 ...

Financial Performance - The company achieved total revenue of 1.742 billion yuan in 2024, a decrease of 7.61% year-on-year, primarily due to a decline in agency product and testing service income [3] - Self-produced products generated revenue of 837 million yuan, remaining stable compared to the previous year [3] - Net profit attributable to shareholders was 258 million yuan, a year-on-year increase of 0.56% [3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 220 million yuan, an increase of 12.67% year-on-year [3] Strategic Focus - The company will continue to implement a strategy centered on in vitro diagnostic instruments and products, aiming for collaborative development between diagnostic products and services [3] - Plans to enhance product variety and quality through continuous technological innovation and product research and development [3] Market Challenges - The in vitro diagnostic industry is facing pressure due to national medical insurance cost control and centralized procurement, impacting short-term performance [9][19] - The company aims to strengthen refined management, implement large-scale production, and optimize the supply chain to improve operational efficiency and market share [10][19] International Expansion - In 2024, the company participated in major overseas exhibitions, expanding its business to six new countries and regions [12] - Plans to accelerate product international market registration and certification, establishing an "International Trade Center" in Shenzhen to enhance international sales capabilities [13] Technological Development - The company is focusing on automation, precision medicine, and personalized diagnostics as key trends in the in vitro diagnostic industry [11][15] - Ongoing investment in R&D to enhance product performance and develop new products in the fields of biochemistry, mass spectrometry, and precision lipid testing [15][16] Future Outlook - The company anticipates that the aging population and increasing life expectancy in China will continue to drive growth in the in vitro diagnostic industry [11] - The company is committed to adapting to industry changes and enhancing its competitive position through strategic adjustments and technological advancements [19]

美康生物（300439）公告，2025年第一季度营业收入3.74亿元，同比下降22.32%。净利润3039.77万 元，同比下降61.57%。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥374,030,860.65, a decrease of 22.32% compared to ¥481,512,053.72 in the same period last year[5] - Net profit attributable to shareholders was ¥30,397,722.74, down 61.57% from ¥79,096,771.20 year-on-year[5] - The total comprehensive income for the period was ¥28,621,792.87, down from ¥78,072,635.19, reflecting a decline of approximately 63.3% year-over-year[22] - Net profit for the period was ¥29,779,054.03, down from ¥78,052,111.07, reflecting a decline of approximately 61.9% year-over-year[22] - Basic and diluted earnings per share both decreased to ¥0.08 from ¥0.21, a drop of approximately 61.9%[23] - Total operating revenue decreased to ¥374,030,860.65 from ¥481,512,053.72, representing a decline of approximately 22.3% year-over-year[21] - Total operating costs reduced to ¥350,212,593.71 from ¥412,341,013.66, a decrease of about 15.1% year-over-year[21] Cash Flow - The net cash flow from operating activities was -¥46,259,188.59, a decline of 605.58% compared to ¥9,149,804.16 in the previous year[5] - Operating cash flow turned negative at -¥46,259,188.59 compared to a positive cash flow of ¥9,149,804.16 in the previous period[24] - Cash inflow from investment activities increased significantly to ¥173,477,532.06 from ¥19,168,033.97, indicating a strong recovery in investment receipts[24] - Net cash flow from investment activities was -$92,666,023.25, improving from -$138,270,881.54 year-over-year[25] - Cash inflow from financing activities was $480,000.00, compared to $30,000,000.00 in the previous period[25] - Net cash flow from financing activities was -$29,809,214.13, worsening from -$20,432,329.74 year-over-year[25] - The net increase in cash and cash equivalents was -$168,774,287.99, compared to -$149,545,907.62 in the previous period[25] - The ending balance of cash and cash equivalents was $557,840,748.36, down from $802,778,150.63 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,587,941,696.34, a decrease of 3.16% from ¥3,705,114,506.80 at the end of the previous year[5] - Current assets decreased from CNY 1,824,194,344.46 to CNY 1,721,424,797.37, representing a decrease of about 5.63%[18] - Cash and cash equivalents decreased from CNY 728,636,326.23 to CNY 559,862,038.24, a reduction of approximately 23.2%[18] - Total liabilities decreased from CNY 771,646,162.98 to CNY 624,691,078.45, a decline of about 19.05%[19] - The company's equity attributable to shareholders increased from CNY 2,939,828,873.18 to CNY 2,970,496,731.95, an increase of approximately 1.04%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,048, with the largest shareholder holding 28.36% of the shares[14] Operational Strategy - The company plans to enhance refined management and optimize the supply chain to improve operational efficiency and increase market share in the biochemical and immunological product sectors[9] - The company aims to accelerate its overseas market expansion as part of its growth strategy[9] Other Financial Metrics - The weighted average return on equity was 1.03%, down from 2.87% in the same period last year, reflecting a decrease of 1.84%[5] - The company reported a significant increase in government subsidies, amounting to ¥11,172,090.16, a rise of 67.84% compared to ¥6,656,517.70 in the previous year[12] - The company experienced a 487.93% increase in notes receivable, reaching ¥1,393,694.65, primarily due to settlements using commercial acceptance bills[11] - Accounts receivable increased from CNY 553,022,297.52 to CNY 566,641,388.55, an increase of about 2.02%[18] - Inventory decreased from CNY 286,010,777.60 to CNY 271,270,681.93, a decrease of approximately 5.15%[18] - The deferred income tax assets increased from CNY 40,748,986.09 to CNY 49,302,563.68, an increase of about 21.3%[19] - The company's retained earnings increased from CNY 1,323,727,670.30 to CNY 1,354,125,393.04, an increase of approximately 2.29%[20] - Research and development expenses were ¥35,830,195.42, down from ¥38,296,282.28, a reduction of about 12.8% year-over-year[21] - Other income increased to ¥11,172,090.16 from ¥6,656,517.70, marking an increase of approximately 67.5% year-over-year[21] - The company reported an investment loss of ¥2,738,528.61 compared to a gain of ¥1,680,076.74 in the previous period, indicating a significant downturn in investment performance[21] Accounting and Reporting - The first quarter report was not audited[26] - The company will implement new accounting standards starting in 2025[27]

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-027 美康生物科技股份有限公司 关于控股子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，美康生物科技股份有限公司（以下简称"公司"）的控股子公司江西 美康盛德生物科技有限公司（以下简称"江西美康"）取得了由江西省药品监督 管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》（以下简称 "《注册证》"），具体情况如下： 一、医疗器械注册证的具体情况 | 序号 | 注册人名称 | 产品名称 | 注册证编号 | 注册证有效期间 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 江西美康 | 伏立康唑检测试剂盒（液 | 赣械注准 | 2025 年 4 月 17 日至 | 用于人血清中伏立康唑浓度 | | | | | | | 的体外定量检测，可适用于 | | | | 相色谱-串联质谱法） | 20252400051 | 2030 年 4 月 16 日 | 临床监测患者伏立康唑的血 ...

证券代码：300439 证券简称：美康生物 公告编号：2025-028 美康生物科技股份有限公司 2025 年 4 月 25 日，美康生物科技股份有限公司（以下简称"公司"）召开 第五届董事会第十三次会议及第五届监事会第十二次会议，分别审议通过了《关 于公司<2025 年第一季度报告>的议案》。 为使投资者全面了解公司 2025 年第一季度的经营成果、财务状况等情况， 公司《2025 年第一季度报告全文》于 2025 年 4 月 26 日在中国证券监督管理委员 会指定的创业板信息披露网站上披露，敬请投资者注意查阅。 巨潮资讯网：http://www.cninfo.com.cn 美康生物科技股份有限公司 特此公告。 2025 年第一季度报告披露提示性公告 美康生物科技股份有限公司 董事会 2025 年 4 月 26 日 1 / 1 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300439 证券简称：美康生物 公告编号：2025-015 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 立信会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所未变更。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以2024年12月31日的总股本383,949,815股为基数，向全 体股东每10股派发现金红利1.35元（含税），送红股0股（含税），以资本公积金向全体股东每10股转 增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （1）公司主要业务 公司主要从事体外诊断产品的研发 ...

4月18日晚，美康生物(300439)披露2024年年报，公司扣非净利润同比增长12.67%，在质谱、血脂的精 准检测研发合作也有显著进展。公司表示，将继续坚持"以体外诊断仪器为引擎，体外诊断产品为核 心，体外诊断产品+诊断服务协同发展"的战略布局，持续投入研发，进一步丰富自产产品种类，通过 质谱、精准血脂等精准诊断产品打造新的业绩增长点。 2024年，美康生物实现营业收入174242.45万元、同比减少7.61%，主要系代理产品及检测服务收入下降 所致；归属于上市公司股东的净利润和扣非净利润分别为25799.72万元、22040.61万，同比增长 0.56%、12.67%。 美康生物认为，2024年医保控费不断深入，集采扩围，行业增速有所放缓，但IVD（体外诊断）行业作 为医疗器械市场中规模大、增速高的优质赛道，未来仍将是医疗器械细分领域中最具潜力的领域。 从国内市场细分行业来看，体外诊断行业集采不断扩围，未来市场主要份额将集中在头部企业。中国体 外诊断市场由生化诊断、免疫诊断、分子诊断、血液诊断、微生物诊断、POCT等细分领域构成。美康 生物分析，首先，生化诊断覆盖人群规模大、服务及服务用户占比高，未来掌 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-018 美康生物科技股份有限公司 2024 年度募集资金存放与使用情况的专项报告 金采取了专户存储制度。 （二）以前年度已使用情况、本年度使用情况及结余情况 公司募集资金使用情况为： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集 资金管理和使用的监管要求（2022年修订）》（证监会公告〔2022〕15号）、《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》以及 《深圳证券交易所创业板上市公司自律监管指南第2号——公告格式》的相关规 定，本公司将2024年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2021]310号文"关于同意美康生物科技 股份有限公司向特定对象发行股票注册的批复"核准，同意公司向特定对象发行 39,999,995股人民币普通股（A股），每股发行价为人民币15.00元，共募集 ...